Monaco Asset Management SAM Grows Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Monaco Asset Management SAM increased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 288.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 291,364 shares of the company’s stock after buying an additional 216,364 shares during the period. Monaco Asset Management SAM owned about 0.12% of Maravai LifeSciences worth $1,588,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in MRVI. FNY Investment Advisers LLC boosted its holdings in Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after buying an additional 6,000 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in Maravai LifeSciences in the 3rd quarter valued at about $47,000. Farther Finance Advisors LLC grew its stake in Maravai LifeSciences by 3,541.4% in the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after acquiring an additional 9,916 shares during the last quarter. Atria Investments Inc acquired a new stake in Maravai LifeSciences in the 4th quarter valued at about $58,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Maravai LifeSciences in the 3rd quarter valued at about $105,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Insider Activity at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares in the company, valued at approximately $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.63% of the company’s stock.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $2.42 on Friday. The firm has a market capitalization of $611.12 million, a P/E ratio of -1.48 and a beta of -0.08. The stock has a fifty day moving average price of $4.36 and a 200 day moving average price of $6.11. Maravai LifeSciences Holdings, Inc. has a 52 week low of $2.41 and a 52 week high of $11.56. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MRVI. Bank of America lowered their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Robert W. Baird cut shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $9.00 to $3.00 in a research note on Wednesday, February 26th. Guggenheim began coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Finally, Wolfe Research began coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $9.28.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.